HURA — TuHURA Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$2.02
-$0.00 (-0.25%)
TuHURA Biosciences Inc (HURA) is a biotechnology company listed on NASDAQ. It is led by James A. Bianco M.D., based in 10500 University Center Drive, Tampa, FL, United States, 33612, with about 22 employees. TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Latest reported HURA revenue for 2025-09-30 was $0. Net income was -$23.3M. HURA currently screens at market cap $125.1M.
Use this HURA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the HURA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the HURA SEC filings page. Lician reads the product cache first so this HTML stays unique to TuHURA Biosciences Inc even when a live quote feed is slow.
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
HURA Key Statistics
Market Cap
$125.14M
Volume
238,377
Previous Close
$2.15
Day Range
$2.03 – $2.19
EPS
-$1.21
Revenue
$0.00
Net Income
-$21.68M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
22
HURA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$21.68M | -$29.32M | -$22.66M |
| EPS (Diluted) | -$1.21 | -$2.47 | $0.00 |
Total Assets
$19.97M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$12.66M
Operating Cash Flow
-$14.73M
Free Cash Flow
$0.00
TuHURA Biosciences Inc Company Information
- President, CEO & Director
- James A. Bianco M.D.
- Headquarters
- 10500 University Center Drive, Tampa, FL, United States, 33612
- Website
- www.tuhurabio.com
- Phone
- 813 875 6600
- IPO / Founded
- 2013-02-22
- Sector
- Healthcare
- Industry
- Biotechnology